MADRIGAL PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| MADRIGAL PHARMACEUTICALS INC. | ||
| Date: February 28, 2024 | By: | /s/ WILLIAM J. SIBOLD |
|---|---|---|
| William J. Sibold | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints William J. Sibold, Alex G. Howarth and Brian J. Lynch, and each or either of them, acting individually, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Report, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or any of them, or their or his or her substitutes, may lawfully do or cause to be done or by virtue hereof.
Pursuant to the requirements of the Exchange Act, as amended, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signatures | Title | Date |
|---|---|---|
| /s/ WILLIAM J. SIBOLD | President and Chief Executive Officer (Principal Executive Officer) | February 28, 2024 |
| William J. Sibold | ||
| /s/ ALEX G. HOWARTH | Chief Financial Officer (Principal Accounting and Financial Officer) | February 28, 2024 |
| Alex G. Howarth | ||
| /s/ JULIAN C. BAKER | Director | February 28, 2024 |
| Julian C. Baker | ||
| /s/ REBECCA TAUB, M.D. | Director | February 28, 2024 |
| Rebecca Taub, M.D. | ||
| /s/ FRED B. CRAVES, PH.D. | Director | February 28, 2024 |
| Fred B. Craves, Ph.D. | ||
| /s/ KENNETH M. BATE | Director | February 28, 2024 |
| Kenneth M. Bate | ||
| /s/ PAUL A. FRIEDMAN, M.D. | Director | February 28, 2024 |
| Paul A. Friedman, M.D. | ||
| /s/ RAYMOND CHEONG | Director | February 28, 2024 |
| Raymond Cheong | ||
| Signatures | Title | Date |
|---|---|---|
| /s/ RICHARD S. LEVY, M.D. | Director | February 28, 2024 |
| Richard S. Levy, M.D. | ||
| /s/ JAMES M. DALY | Director | February 28, 2024 |
| James M. Daly | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Financial Statements: | |
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations | F-5 |
| Consolidated Statements of Comprehensive Loss | F-6 |
| Consolidated Statements of Stockholders’ Equity | F-7 |
| Consolidated Statements of Cash Flows | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.